Cencora Inc. (COR)vsJohnson & Johnson (JNJ)
COR
Cencora Inc.
$359.03
-0.58%
HEALTHCARE · Cap: $66.67B
JNJ
Johnson & Johnson
$282.84
-1.12%
HEALTHCARE · Cap: $682.52B
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 240% more annual revenue ($337.40B vs $99.33B). JNJ leads profitability with a 16.2% profit margin vs 1.0%. COR appears more attractively valued with a PEG of 0.77. COR earns a higher WallStSmart Score of 62/100 (C+).
COR
Buy62
out of 100
Grade: C+
JNJ
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.6%
Fair Value
$193.43
Current Price
$359.03
$165.60 premium
Intrinsic value data unavailable for JNJ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 95 in profit
Large-cap with strong market position
Growing faster than its price suggests
Generating 2.7B in free cash flow
Mega-cap, among the largest globally
Strong operational efficiency at 26.6%
Generating 6.4B in free cash flow
Areas to Watch
Trading at 18.6x book value
1.0% margin — thin
Operating margin of 1.4%
Elevated debt levels
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : COR
The strongest argument for COR centers on Return on Equity, Market Cap, PEG Ratio. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.
Bear Case : COR
The primary concerns for COR are Price/Book, Profit Margin, Operating Margin. Debt-to-equity of 3.06 is elevated, increasing financial risk. Thin 1.0% margins leave little buffer for downturns.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.
Key Dynamics to Monitor
COR profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
COR carries more volatility with a beta of 0.57 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
COR scores higher overall (62/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?